These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30730675)

  • 1. Pharmaceutical research and development: a new system is needed.
    Prescrire Int; 2017 May; 26(182):130-135. PubMed ID: 30730675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Price differentiation and transparency in the global pharmaceutical marketplace.
    Ridley DB
    Pharmacoeconomics; 2005; 23(7):651-8. PubMed ID: 15987224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Talkin' About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices.
    Shaw B; Mestre-Ferrandiz J
    Pharmacoeconomics; 2020 Feb; 38(2):125-134. PubMed ID: 31956967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus document on European brain research.
    Olesen J; Baker MG; Freund T; di Luca M; Mendlewicz J; Ragan I; Westphal M
    J Neurol Neurosurg Psychiatry; 2006 Aug; 77 Suppl 1(Suppl 1):i1-49. PubMed ID: 16845120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
    Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
    PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WHO's role in the global health system: what can be learned from global R&D debates?
    Moon S
    Public Health; 2014 Feb; 128(2):167-72. PubMed ID: 24393496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cautionary Notes on a Global Tiered Pricing Framework for Medicines.
    Williams OD; Ooms G; Hill PS
    Am J Public Health; 2015 Jul; 105(7):1290-3. PubMed ID: 25973806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drugs in the European Union: the health-market complex].
    Antoñanzas F; Rodríguez R; Sacristán JA; Illa R
    Gac Sanit; 2005; 19(2):151-67. PubMed ID: 15860163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmaceutical industry as a medicines provider.
    Henry D; Lexchin J
    Lancet; 2002 Nov; 360(9345):1590-5. PubMed ID: 12443614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tying Medicare Part B Drug Prices to International Reference Pricing Will Devastate R&D.
    Schulthess D; Gassull D; Maisel S
    Ther Innov Regul Sci; 2019 Nov; 53(6):746-751. PubMed ID: 31771361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical net price transparency across european markets: Insights from a multi-agent simulation model.
    Riccaboni M; Swoboda T; Van Dyck W
    Health Policy; 2022 Jun; 126(6):534-540. PubMed ID: 35459584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Legal and policy foundations for global generic competition: Promoting affordable drug pricing in developing societies.
    Zapatero Miguel P
    Glob Public Health; 2015; 10(8):901-16. PubMed ID: 25737069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.
    Dranitsaris G; Ortega A; Lubbe MS; Truter I
    J Oncol Pharm Pract; 2012 Mar; 18(1):57-67. PubMed ID: 21382915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Securing sustainable price levels of innovative anticancer drugs: How to move forward?
    Franzen N; Retèl V; van Harten W
    J Cancer Policy; 2021 Mar; 27():100266. PubMed ID: 35559942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.